Product Pathways - PI3K / Akt Signaling
GSK-3β Blocking Peptide #1073
|1073S||100 µg||---||In Stock||---|
|1073||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
This peptide is used specifically to block GSK-3β (27C10) Rabbit mAb #9315 reactivity.
The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks GSK-3beta (27C10) Rabbit mAb #9315 by immunohistochemistry.
Western blot analysis of extracts from HeLa, COS, and NIH/3T3 cells using GSK-3β (27C10) Rabbit mAb #9315 (left) or the same antibody pre-incubated in the presence of GSK-3β Blocking Peptide (right).
Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols.
Directions For Use
For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 µl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.
Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in Dictyostelium and is a component of the Wnt signaling pathway required for Drosophila, Xenopus, and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.